Literature DB >> 31275783

Proposal of classification of "chronic kidney disease (CKD) with diabetes" in clinical setting.

Munehiro Kitada1,2, Daisuke Koya1,2.   

Abstract

The natural history of typical and classical "diabetic nephropathy" has been described as high levels of albuminuria and subsequent renal function decline. However, recent decades, the cases, who show the reduced glomerular filtration rate (GFR) without the progression of albuminuria, has been increased. "Diabetic kidney disease (DKD)" is a concept that widely recognizes the pathophysiological change induced by diabetes as the onset and progressive factor of renal injury and renal function decline, regardless of the level of albuminuria. However, we may confuse that "chronic kidney disease (CKD) with diabetes" is "DKD". Therefore, to choose the appropriate treatment that should be prioritized in the clinical setting, we propose that "CKD with diabetes" is classified as "DKD", "non-DKD (NDKD) with diabetes" or "combined disease of DKD and NDKD".

Entities:  

Keywords:  Chronic kidney disease; Diabetes; Diabetic kidney disease; Non-diabetic kidney disease

Year:  2019        PMID: 31275783      PMCID: PMC6592982          DOI: 10.1007/s13340-019-00396-8

Source DB:  PubMed          Journal:  Diabetol Int        ISSN: 2190-1678


  8 in total

1.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

2.  Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.

Authors:  Jens Oellgaard; Peter Gæde; Peter Rossing; Frederik Persson; Hans-Henrik Parving; Oluf Pedersen
Journal:  Kidney Int       Date:  2017-02-07       Impact factor: 10.612

3.  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.

Authors:  Toshiharu Ninomiya; Vlado Perkovic; Bastiaan E de Galan; Sophia Zoungas; Avinesh Pillai; Meg Jardine; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Stephen Macmahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

4.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

5.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

6.  Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Brad H Rovin; Dawn J Caster; Daniel C Cattran; Keisha L Gibson; Jonathan J Hogan; Marcus J Moeller; Dario Roccatello; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Jürgen Floege
Journal:  Kidney Int       Date:  2019-02       Impact factor: 10.612

7.  Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Jürgen Floege; Sean J Barbour; Daniel C Cattran; Jonathan J Hogan; Patrick H Nachman; Sydney C W Tang; Jack F M Wetzels; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Brad H Rovin
Journal:  Kidney Int       Date:  2019-02       Impact factor: 10.612

8.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.